• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

COVID-19 Can Cause New Cholesterol Problems. What to Know
Not long after the start of the global coronavirus pandemic, it was apparent that many people infected with SARS-CoV-2 were developing persistent and, in some cases, debilitating health problems. Now known widely as post-Covid syndrome or Long COVID, the most common symptoms of this condition are fatigue, attention problems, headaches, muscle or joint pain, and weakness. But those are just the start. Medical researchers have also linked SARS-CoV-2 to lingering complications in multiple organs and systems, and some recent work has found that new-onset cholesterol problems may be an under-recognized but common complication o...
Source: TIME: Health - May 30, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

10 New Year ’s Resolutions Doctors Actually Want You to Make
Each year, Americans’ most popular New Year’s resolutions are more or less the same: get healthy, get organized, save money. But doctors at the American Medical Association (AMA) have some more specific thoughts in mind for 2019. The AMA this week released a list of 10 wellness-focused resolutions that could “help Americans make the most impactful, long-lasting improvements to their health in 2019.” Here’s what they are — and how to make them happen. Learn your risk for type 2 diabetes Diabetes is one of the most common chronic health conditions in the U.S., affecting an estimated 30 mil...
Source: TIME: Health - December 21, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime Holidays 2018 public health Source Type: news

10 New Year's Resolutions Doctors Actually Want You to Make
Each year, Americans’ most popular New Year’s resolutions are more or less the same: get healthy, get organized, save money. But doctors at the American Medical Association (AMA) have some more specific thoughts in mind for 2019. The AMA this week released a list of 10 wellness-focused resolutions that could “help Americans make the most impactful, long-lasting improvements to their health in 2019.” Here’s what they are — and how to make them happen. Learn your risk for type 2 diabetes Diabetes is one of the most common chronic health conditions in the U.S., affecting an estimated 30 mil...
Source: TIME: Health - December 21, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime Holidays 2018 public health Source Type: news